Bayer to Terminate its JV Agreement with CRISPR Therapeutics

 Bayer to Terminate its JV Agreement with CRISPR Therapeutics

Bayer to Terminate its JV Agreement with CRISPR Therapeutics

Shots:

  • CRISPR to get direct management of Casebia Therapeutics, which would focus on developing lead programs in hemophilia, ophthalmology and autoimmune diseases. Bayer to get an option for two products at IND submission
  • In Dec’2015, Bayer and CRISPR collaborated to create JV (Casebia) for the discovery, development & commercialization of breakthrough therapies to cure blood disorders, blindness, and congenital heart disease, combining CRISPR-Cas9 gene-editing technology & IP with Bayer’s protein engineering expertise
  • CRISPR will advance the Casebia’s programs to the next phase of development with its expected transaction to be closed in Q4’19

Click here to­ read full press release/ article | Ref: CRISPR Therapeutics | Image: PRNewswire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post